Hostname: page-component-848d4c4894-4rdrl Total loading time: 0 Render date: 2024-06-26T04:27:04.685Z Has data issue: false hasContentIssue false
  • English
  • Français

A novel approach to patients with schizophrenia and type 2 diabetes showing low treatment compliance

Published online by Cambridge University Press:  01 September 2022

P. Argitis ,
A. Karampas ,
P. Bringiotti ,
S. Karavia ,
O. Pikou  and
F.-E. Kakavitsas
P. Argitis*
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
A. Karampas
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
P. Bringiotti
Affiliation:
General Hospital of Corfu, General Medicine, corfu, Greece
S. Karavia
Affiliation:
General Hospital of Corfu, Psychiatric, Corfu, Greece
O. Pikou
Affiliation:
General Hospital of Corfu, Dermatology, Corfu, Greece
F.-E. Kakavitsas
Affiliation:
General Hospital of Corfu, General Medicine, corfu, Greece
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Patients with schizophrenia usually demonstrate low compliance to medication. This could be a component of the disorder or a fact that they are not being properly cared.

Objectives

To prevent this in, we tried to treat these patients with long term action antidiabetic agents, in order to achieve better compliance.

Methods

HbA1C measurements of patients suffering from schizophrenia and at the same time receiving oral antidiabetic treatment were conducted. 62 patients were found that fell under the criteria of non regulated type 2 diabetes and at the same time presented less than 70% complied with their antidiabetic pharmaceutical treatment. We modified the antidiabetic treatment of these patients, with the introduction of dulaglutide.

Results

Without intervening with their nutritional habits there was a decline in HbA1C measurements from the average rate of 9,4% to the average rate of 7,6%, as well as an average 6,31% reduction of their body weight.

Conclusions

Due to the improvement of the general medical condition of these patients, the answer to the question whether these patients should be treated with a long term antidiabetic medicines, is positive. The arrival of new long term action antidiabetic medicines in the near future, promises to improve the life quality of schizophrenic patients furthermor.

Disclosure

No significant relationships.

Keywords

schizophréniaType 2 diabetes
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S768
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.